Five Years Follow up: Add on Intravenous Ketamine for Major Depressive Disorder
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Followin Ketamine Treatment
- Sponsor
- The Chaim Sheba Medical Center
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- Time to relapse
- Last Updated
- 6 years ago
Overview
Brief Summary
Results of the study and of 5 years follow up of depressed patients who participated in the study during 2014-2015. We will locate the participants and will interview them will use the same questionnaires to evaluate their depressive symptoms. We will also measure the time to relapse.
Detailed Description
Anamnestic data will be collected from the patients, in addition, depressive symptoms will be measured using Montgomery Asberg Depression Scale (MADRAS). In addition, the Clinical Global Severity Scale (CGI-S) and Clinical Global Improvement (CGI-I) were performed 2 hours after treatment. In addition, we performed to prolong the time to relapse in this patient.
Investigators
Revital Amiaz
Head of Psychiatry Department B
The Chaim Sheba Medical Center
Eligibility Criteria
Inclusion Criteria
- •Participants in the ketamine study
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Time to relapse
Time Frame: 5 years
Medications